EUVIMEDTutustu EUVIMEDiin
Leserbrief

Managing the significant drug‐drug interaction between isavuconazole and tacrolimus in solid organ transplant recipients

Jessica Hedvat iD, Nicholas W Lange iD, Jenna L Scheffert, Marcus R Pereira iD, David M Salerno iD

Clinical Transplantation · 2024

DOI: 10.1111/ctr.15278 ↗

At a glance

Leserbrief in Clinical Transplantation, 2024. Written by Jessica Hedvat and 4 co-authors. Institution: Department of Pharmacy, NewYork-Presbyterian Hospital, New York City, New York, USA. Major MEDLINE topics: Tacrolimus, Organ Transplantation, Nitriles, Pyridines. 5 references.

TiivistelmäSubjectsBibliografiset tiedotCiteRelated studies

Abstract (original language)

Managing the significant drug-drug interaction between isavuconazole and tacrolimus in solid organ transplant recipientsWhile fungal infections are relatively uncommon in solid organ transplant (SOT) recipients, they are associated with significant morbidity and mortality.1 Further, either treatment or prophylaxis against fungal infections usually involves the use of azole antifungals.2 Isavuconazonium sulfate has become an attractive option for either prophylaxis or treatment of various mold species in high-risk patients after transplant due to its broad spectrum of activity, limited need for monitoring, and more tolerable side effect profile compared to posaconazole and voriconazole.According to the product labeling, isavuconazole is listed as a moderate inhibitor of cytochrome P450 3A4 and a mild inhibitor of P-glycoprotein and organic cation transporter 2, and caution is advised when using isavuconazole and tacrolimus concomitantly. 3 There are currently conflicting data on the degree of the interaction in SOT recipients and whether empiric tacrolimus dose adjustments are needed when isavuconazole is initiated.4,5 We conducted this F I G U R E 1 (A) Tacrolimus dose-corrected trough concentrations and (B) tacrolimus trough concentrations.

Subjects

MeSH terms (MEDLINE)

TacrolimusOrgan TransplantationNitrilesPyridinesTriazolesHumansImmunosuppressive AgentsDrug InteractionsTransplant Recipients

Substances

TacrolimusisavuconazoleImmunosuppressive AgentsNitrilesPyridinesTriazoles

Authors and institutions

  • Department of Pharmacy, NewYork-Presbyterian Hospital, New York City, New York, USA.
  • Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York City, New York, USA.

ORCID profiles: Jessica Hedvat, Nicholas W Lange, Marcus R Pereira, David M Salerno

Cite

APA

Hedvat, J., Lange, N. W., Scheffert, J. L., Pereira, M. R., & Salerno, D. M. (2024). Managing the significant drug‐drug interaction between isavuconazole and tacrolimus in solid organ transplant recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.15278

Vancouver

Hedvat J, Lange NW, Scheffert JL, Pereira MR, Salerno DM. Managing the significant drug‐drug interaction between isavuconazole and tacrolimus in solid organ transplant recipients. Clinical Transplantation. 2024. doi:10.1111/ctr.15278

BibTeX
@article{Hedvat2024,
  author = {Hedvat, Jessica and Lange, Nicholas W and Scheffert, Jenna L and Pereira, Marcus R and Salerno, David M},
  title = {Managing the significant drug‐drug interaction between isavuconazole and tacrolimus in solid organ transplant recipients},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.15278}
}
Start for free →